CFTR and risk of pulmonary arterial hypertension: a case report and mendelian randomization study Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020
Gut microbiota and pulmonary hypertension:a Mendelian randomization study Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020
Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model Source: Eur Respir J, 50 (2) 1700740; 10.1183/13993003.00740-2017 Year: 2017
Novel biomarkers for risk stratification in pulmonary arterial hypertension Source: ERJ Open Res 2015; 1: 00008-2015 Year: 2015
Kidney function and obstructive lung disease: a bidirectional Mendelian randomisation study Source: Eur Respir J, 58 (6) 2100848; 10.1183/13993003.00848-2021 Year: 2021
Risk assessment in scleroderma patients with newly diagnosed pulmonary arterial hypertension: application of the ESC/ERS risk prediction model Source: Eur Respir J, 52 (4) 1800497; 10.1183/13993003.00497-2018 Year: 2018
Severe pulmonary sarcoidosis: definition and risk stratification Source: Virtual Congress 2020 – Severe thoracic sarcoidosis : where do we stand ? Year: 2020
Genetically increased circulating FUT3 level leads to reduced risk of idiopathic pulmonary fibrosis: a Mendelian randomisation study Source: Eur Respir J, 59 (2) 2003979; 10.1183/13993003.03979-2020 Year: 2022
Early risk prediction in idiopathic versus connective tissue disease-associated pulmonary arterial hypertension: call for a refined assessment Source: ERJ Open Res, 7 (3) 00854-2020; 10.1183/23120541.00854-2020 Year: 2021
Pulmonary hypertension and COPD: Clinical assessment and biomarkers Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II Year: 2013
Risk assessment, therapy and cardiovascular comorbidity in patients with pulmonary arterial hypertension Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension Year: 2020
ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre Source: Eur Respir J 2012; 39: 945-955 Year: 2012
Prevalence of pulmonary hypertension in pulmonary sarcoidosis: the first large European prospective study Source: Eur Respir J, 54 (4) 1900897; 10.1183/13993003.00897-2019 Year: 2019
Variation in mortality from pulmonary hypertension by aetiology Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015
Prevalence of sarcoidosis-associated pulmonary hypertension: cumulative analysis of two PULSAR studies Source: Eur Respir J, 55 (2) 1902223; 10.1183/13993003.02223-2019 Year: 2020
Risk factors for chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2009; 33: 325-331 Year: 2009
Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension Source: Eur Respir J, 51 (5) 1702310; 10.1183/13993003.02310-2017 Year: 2018
Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort Source: Eur Respir J, 57 (6) 2002591; 10.1183/13993003.02591-2020 Year: 2021
Age, risk and outcomes in idiopathic pulmonary arterial hypertension Source: Eur Respir J, 51 (5) 1800629; 10.1183/13993003.00629-2018 Year: 2018
Distance assessment of the risk of pulmonary hypertension associated with connective tissue diseases: do biomarkers help? Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021